Nantahala Capital Management’s Exagen XGN Stock Holding History
Bought
Maintained
Sold
Other funds holding XGN
RI
KCM
SAM
WC
Nantahala Capital Management's XGN Position: Q3 2025 in Review
Nantahala Capital Management sold out of Exagen (XGN) in Q3 2025, closing a stake of 61,186 shares — an estimated $427K sold.
Nantahala Capital Management first reported a position in XGN in Q1 2021 and held it in 18 quarters. The position peaked at $6.55M in Q1 2021. 62 funds tracked by Wall St. Rank hold XGN as of Q3 2025.
- Nantahala Capital Management reported no remaining Exagen position as of Q3 2025 after selling out during the quarter.
- Nantahala Capital Management sold 61,186 Exagen shares in Q3 2025, an estimated $427K.
- Nantahala Capital Management first reported a position in Exagen in Q1 2021 and held it in 18 quarters.
- Nantahala Capital Management's Exagen position peaked at $6.55M in Q1 2021.
- 62 funds tracked by Wall St. Rank held Exagen as of Q3 2025.
Based on Nantahala Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.